Apellis Pharmaceuticals Market Research Report
Company Overview
Name
Apellis Pharmaceuticals, Inc.
Mission
Apellis combines courageous science and compassion to develop life-changing medicines for some of the most challenging diseases patients face.
Founded
Apellis Pharmaceuticals was founded more than a decade ago in a university lab in Kentucky.
Founders
- Cedric Francois, MD, PhD, Co-Founder & CEO/President
- Pascal Deschatelets, PhD, Co-Founder & CSO
- Alec Machiels, JD, MBA, Co-Founder
Key People
- Cedric Francois, MD, PhD: Co-Founder & Chief Executive Officer/President
- Caroline Baumal, MD: Chief Medical Officer
- Mark DeLong: Chief Business & Strategy Officer
- Pascal Deschatelets, PhD: Co-Founder & Chief Scientific Officer
- Jeffrey Eisele, PhD: Chief Development Officer
- Karen Lewis: Chief People Officer
- Nur Nicholson: Chief Technical Operations Officer
- Timothy Sullivan: Chief Financial Officer
- Adam Townsend: Chief Operating Officer
- David Watson, JD: General Counsel
Headquarters
No information is available on the exact location of the headquarters.
Number of Employees
No information is available on the number of employees.
Revenue
No information is available on the company's revenue.
Known For
Apellis Pharmaceuticals is known for advancing treatment in a broad range of debilitating diseases by targeting the complement cascade within the immune system. Their groundbreaking products focus on targeting C3, the central protein of this cascade.
Products
1. SYFOVRE® (pegcetacoplan injection)
- Disease Targeted: Geographic Atrophy (GA)
- Approval Status: Marketed in the US
- Description: SYFOVRE® is the first-ever therapy for geographic atrophy, a leading cause of blindness worldwide.
- Key Features: This product marks the introduction of a new class of complement medicine not seen in 15 years.
2. EMPAVELI® (pegcetacoplan)
- Disease Targeted: Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Approval Status: Marketed in the US
- Description: EMPAVELI® is targeted towards treating PNH, with ongoing studies for additional indications like IC-MPGN & C3G and HSCT-TMA.
Recent Developments
New Product Launches
- SYFOVRE® and EMPAVELI® have both been launched in the US, marking significant advances in ophthalmology and rare disease treatments respectively.
New Features/Additions
No specific new features or additions to existing products have been documented in the available information.
Partnerships
- Sobi has global co-development and ex-U.S. commercialization rights for systemic pegcetacoplan.
Other Developments
- Apellis is working on nearly a dozen clinical and pre-clinical programs, which span the areas of ophthalmology, rare disease, and neurology, indicating plans for significant research expansion and product development.
- Apellis is focused on advancing gene/RNA therapies and gene-edited therapies as a part of their multiple therapeutic area approach.
Conclusion
Apellis Pharmaceuticals is pioneering complement-targeted therapies, notably with their approved treatments SYFOVRE® and EMPAVELI®. With a continual investment in understanding and harnessing complement science, Apellis is poised to advance treatments across numerous challenging disease landscapes. The company is actively expanding their pipeline with innovative therapies across various stages of clinical development.
